1083168-69-7

Usage

Uses

Used in Pharmaceutical Industry:
(2,3-dihydrobenzofuran-6-yl)methanol is used as a building block for the synthesis of various drugs and bioactive molecules due to its unique chemical structure and potential therapeutic properties.
Used in Organic Chemistry:
(2,3-dihydrobenzofuran-6-yl)methanol is used as a key intermediate in organic chemistry for the development of new chemical compounds and materials.
Used in Drug Discovery:
(2,3-dihydrobenzofuran-6-yl)methanol is used as a starting material in drug discovery processes, contributing to the research and development of novel pharmaceuticals with potential antioxidant and anti-inflammatory activities.

Upstream product

• 299912-77-9 6-(tert-butyl-dimethylsilanyloxy)-[2H]-benzofuran-3-one 
• 227752-25-2 trifluoromethanesulfonic acid benzofuran-6-yl ester 
• 588703-29-1 methyl benzofuran-6-carboxylate 
• 6272-26-0 6-hydroxybenzofuran-3-one 
• 13196-11-7 6-hydroxybenzofuran 
• 377091-18-4 1,4-dibromo-2-(2-bromoethoxy)benzene 
• 50-00-0 formaldehyd 
• 189035-22-1 6-bromo-2,3-dihydro-1-benzofuran 
• 1083168-68-6 methyl 2,3-dihydrobenzofuran-6-carboxylate 

Downstream Products

• 55746-20-8 (2,3-dihydrobenzofuran-6-yl)methanamine 

Relevant academic research and scientific papers

Orally active ghrelin receptor inverse agonists and their actions on a rat obesity model

A series of 2-alkylamino nicotinamide analogs was prepared as orally active ghrelin receptor (ghrelinR) inverse agonists. Starting from compound 1, oral bioavailability was improved by modifying metabolically unstable sites and reducing molecular weight. Brain-permeable compound 33 and compound 24 with low brain permeability were tested in rat models of obesity; 30 mg/kg of compound 33 suppressed weight gain. PK/PD analysis revealed that the anti-obesity effect of ghrelinR inverse agonists depends on their brain concentrations.

MODULATORS OF CFTR

Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette ("ABC") transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator ("CFTR"). The present invention also relates to methods of treating CFTR mediated diseases using compounds of the present invention.